All In Biotech

Drug Trial Radar · NCT00734578

Efficacy and Safety of SPD503 in Combination With Psychostimulants

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination With Psychostimulants in Children and Adolescents Aged 6-17 Years With a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)

Last checked: Nov 20, 2026Latest source record: Jun 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 461 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

461

Actual

Start

Sep 2, 2008

Primary completion

Dec 10, 2009

Study completion Dec 10, 2009

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Aug 14, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of SPD503 in subjects with ADHD when co-administered with psychostimulants in children and adolescents aged 6-17 years with a diagnosis of ADHD with a sub-optimal, partial response to stimulants.

Conditions

  • ADHD

Interventions

  • SPD503-AMDrug

    SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg

  • SPD503-PMDrug

    SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg

  • PlaceboDrug

    Placebo matched to Guanfacine Hydrochloride Extended Release

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 8 - Last Observation Carried Forward (LOCF)Time frame: Baseline and weekly up to 8 weeks

Locations

61 sites in 1 country. Site status is shown where the registry gives one.

  • Harmonex Neuroscience Research

    Dothan, Alabama

  • Melmed Center

    Scottsdale, Arizona

  • Clinical Study Centers, LLC

    Little Rock, Arkansas

  • Valley Clinical Research, Inc.

    El Centro, California

  • Peninsula Research Associates

    Rolling Hills Estates, California

  • UCSD Department of Psychiatry

    San Diego, California

  • University of California, San Francisco

    San Francisco, California

  • Elite Clinical Trials, Inc

    Wildomar, California

  • Florida Clinical Research Center, LLC

    Bradenton, Florida

  • Gulfcoast Clinical Research Center

    Fort Myers, Florida

  • Sarkis Clinical Trials

    Gainesville, Florida

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida

  • Florida Clinical Research Center, LLC

    Maitland, Florida

  • Miami Children's Hospital

    Miami, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • Janus Center for Psychiatric Research

    West Palm Beach, Florida

  • AMR-Baber Research, Inc.

    Naperville, Illinois

  • American Medical Research, Inc

    Oak Brook, Illinois

  • Goldpoint Clinical Research, LLC

    Indianapolis, Indiana

  • Pedia Research

    Newburgh, Indiana

  • Psychiatric Associates

    Overland Park, Kansas

  • Vince and Associates Clinical Research

    Overland Park, Kansas

  • Pedia Research, LLC

    Owensboro, Kentucky

  • Marc Hertzman, MD, PC

    Rockville, Maryland

  • Delmarva Family Resources

    Salisbury, Maryland

  • Massachussests General Hospital

    Cambridge, Massachusetts

  • Neurobehaviorial Medicine

    Bloomfield Hills, Michigan

  • Rochester Center for Behavioral Medicine

    Rochester Hills, Michigan

  • Behavioral Medicine Center

    Troy, Michigan

  • The Center for Pharmaceutical Research

    Kansas City, Missouri

  • Midwest Research Group/St. Charles Psychiatric Associates

    Saint Charles, Missouri

  • Premier Psychiatric Research Inst. LLC

    Lincoln, Nebraska

  • Centers for Psychiatry and Behavioral Medicine

    Las Vegas, Nevada

  • Children's Specialized Hospital

    Toms River, New Jersey

  • Bioscience Research, LLC

    Mount Kisco, New York

  • Richmond Behavioral Associates

    Staten Island, New York

  • Duke University Medical Center ADHD Program

    Durham, North Carolina

  • Triangle Neuropsychiatry, PLLC

    Durham, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Department of Psychiatry, The Ohio State University

    Columbus, Ohio

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.